Study reviews the impact of long COVID on individuals, health systems, and global economies, highlighting the need for a coordinated, patient-centered approach for future research and policy development.
Ascendis Pharma submits sBLA for growth hormone deficiency therapy
TransCon hGH is marketed in the US as SKYTROFA for paediatric GHD. Credit: Drazen Zigic via Shutterstock. Ascendis Pharma has submitted a supplemental biologics licence